STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLSM
  4. [Form 4] BlossomHill Therapeutics, Inc. Insider Trading Activity

BlossomHill insider buys 312K shares at IPO price

BlossomHill Therapeutics, Inc. (BLSM) insider group associated with Cormorant funds reported several equity changes.

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

BlossomHill Therapeutics, Inc. (BLSM) insider group associated with Cormorant funds reported several equity changes. On August 10, 2026, Cormorant-related funds converted Series A and Series B Preferred Stock into an equal number of Common Stock shares in connection with the closing of the company’s initial public offering. The Master Fund also purchased 312,500 Common Stock shares at $16.00 per share, increasing its indirect position. Separately, on August 6, 2026, director and ten percent owner Bihua Chen received a stock option grant for 23,904 shares with a $16.00 exercise price, vesting monthly over three years and expiring on August 5, 2036. The reporting persons state that they may be deemed beneficial owners only to the extent of their pecuniary interest in the reported shares.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Chen Bihua, Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund VI, LP
Role Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 312,500 shs ($5.00M)
Type Security Shares Price Value
Conversion Series A Preferred Stock F2, F1, F3, F4 1,599,993 -- --
Conversion Series B Preferred Stock F2, F5, F3, F4 1,701,541 -- --
Conversion Common Stock F1, F2, F3, F4 1,599,993 -- --
Conversion Common Stock F5, F2, F6, F3, F4 1,701,541 -- --
Purchase Common Stock F7, F8, F3, F4 312,500 $16.00 $5.00M
Grant/Award Director Stock Option (Right to Buy) F9 23,904 $0.00 $0.00
Holdings After Transaction: Director Stock Option (Right to Buy) — 23,904 contracts (Direct); Series A Preferred Stock — 0 contracts (Indirect, See footnotes); Series B Preferred Stock — 0 contracts (Indirect, See footnotes); Common Stock — 3,614,034 shares (Indirect, See footnotes)
Footnotes (9)
  1. F1. Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).
  2. F2. Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
  3. F3. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
  4. F4. Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  5. F5. Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.
  6. F6. Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
  7. F7. The shares purchased are beneficially owned by Master Fund.
  8. F8. Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
  9. F9. 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
Series A Preferred Stock converted 1,599,993 shares of Series A Preferred Stock Converted into Common Stock on August 10, 2026 upon IPO closing
Series B Preferred Stock converted 1,701,541 shares of Series B Preferred Stock Converted into Common Stock on August 10, 2026 upon IPO closing
Common Stock purchased 312,500 shares at $16.00 per share Indirectly purchased by Cormorant Global Healthcare Master Fund on August 10, 2026
Director Stock Options granted 23,904 options at $16.00 exercise price Granted to Bihua Chen on August 6, 2026, expiring August 5, 2036
Option vesting schedule 1/36th of shares vest monthly over 3 years Vesting begins after August 6, 2026 for Chen’s option grant
Reported Common Stock holdings after purchase 959,090 shares beneficially owned by Master Fund Part of aggregate holdings reported in footnote F8 after the 312,500-share purchase
automatic conversion financial
"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted"
initial public offering financial
"automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
pecuniary interest financial
"disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest"
ten percent owner regulatory
"reporting persons include a director and ten percent owner"
Director Stock Option financial
"Director Stock Option (Right to Buy) with an exercise price of $16.0000"

FAQ

What preferred stock did BLSM insiders convert into common shares?
On August 10, 2026, Cormorant-related funds converted 1,599,993 shares of Series A Preferred Stock and 1,701,541 shares of Series B Preferred Stock of BlossomHill Therapeutics, Inc. into an equal number of Common Stock shares upon the closing of the company’s initial public offering.

How many BLSM common shares were purchased and at what price?
Cormorant Global Healthcare Master Fund purchased 312,500 shares of BlossomHill Therapeutics, Inc. Common Stock at a price of $16.00 per share. These shares are reported as being beneficially owned by the Master Fund and held indirectly by the reporting persons.

What stock option grant did Bihua Chen receive at BLSM?
Director and ten percent owner Bihua Chen received a grant of 23,904 Director Stock Options with an exercise price of $16.00 per share. The options expire on August 5, 2036 and vest in equal monthly installments over three years starting August 6, 2026.

How do the BLSM preferred stock conversions relate to the IPO?
Each share of Series A and Series B Preferred Stock of BlossomHill Therapeutics, Inc. automatically converted into 1 share of Common Stock upon the closing of the company’s initial public offering, without payment of further consideration. The preferred stock had no expiration date before this automatic conversion.

Who are the Cormorant funds involved in the BLSM Form 4 filing?
The filing for BlossomHill Therapeutics, Inc. involves Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund V, LP, and Cormorant Private Healthcare Fund VI, LP, all managed by Cormorant Asset Management, LP, with Bihua Chen as manager.

Do the BLSM reporting persons claim full beneficial ownership of the shares?
No. The reporting persons state that each of them disclaims beneficial ownership of the reported BlossomHill Therapeutics, Inc. shares except to the extent of its or her pecuniary interest. They indicate the filing should not be construed as an admission of beneficial ownership for Section 16(a) or other purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chen Bihua
(Last)(First)(Middle)
C/O CORMORANT ASSET MANAGEMENT LP
200 CLARENDON STREET, 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BlossomHill Therapeutics, Inc. [ BLSM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/10/2026C1,599,993(1)A(2)1,599,993(1)ISee footnotes(3)(4)
Common Stock08/10/2026C1,701,541(5)A(2)3,301,534(6)ISee footnotes(3)(4)
Common Stock08/10/2026P312,500(7)A$163,614,034(8)ISee footnotes(3)(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (Right to Buy)$1608/06/2026A23,904 (9)08/05/2036Common Stock23,904$023,904D
Series A Preferred Stock(2)08/10/2026C1,599,993 (2) (2)Common Stock1,599,993(1)(2)0ISee footnotes(3)(4)
Series B Preferred Stock(2)08/10/2026C1,701,541 (2) (2)Common Stock1,701,541(5)(2)0ISee footnotes(3)(4)
1. Name and Address of Reporting Person*
Chen Bihua
(Last)(First)(Middle)
C/O CORMORANT ASSET MANAGEMENT LP
200 CLARENDON STREET, 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
XDirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Asset Management, LP
(Last)(First)(Middle)
200 CLARENDON STREET 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Global Healthcare Master Fund, LP
(Last)(First)(Middle)
200 CLARENDON STREET 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Private Healthcare Fund III LP
(Last)(First)(Middle)
200 CLARENDON STREET 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Private Healthcare Fund V LP
(Last)(First)(Middle)
200 CLARENDON STREET 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Private Healthcare Fund VI, LP
(Last)(First)(Middle)
200 CLARENDON STREET 50TH FLOOR
(Street)
BOSTON MASSACHUSETTS 02116
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below).
2. Each share of Series A Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
3. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund V, LP ("Fund V") and Cormorant Private Healthcare Fund VI, LP ("Fund VI"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP III, LLC ("GP III"), Cormorant Private Healthcare GP V, LLC ("GP V") and Cormorant Private Healthcare GP VI, LLC ("GP VI") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively.
4. Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
5. Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI.
6. Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
7. The shares purchased are beneficially owned by Master Fund.
8. Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI.
9. 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
Remarks:
Master Fund, Fund III, Fund V and Fund VI may be deemed directors by deputization by virtue of their representation on the board of directors of the Issuer.
/s/ Bihua Chen08/10/2026
CORMORANT ASSET MANAGEMENT, LP By: /s/ Bihua Chen, Managing Member08/10/2026
CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner By: /s/ Bihua Chen, Managing Member08/10/2026
CORMORANT PRIVATE HEALTHCARE FUND III, LP By: Cormorant Private Healthcare GP III, LLC, its General Partner By: /s/ Bihua Chen, Managing Member08/10/2026
CORMORANT PRIVATE HEALTHCARE FUND V, LP By: Cormorant Private Healthcare GP V, LLC, its General Partner By: /s/ Bihua Chen, Managing Member08/10/2026
CORMORANT PRIVATE HEALTHCARE FUND VI, LP By: Cormorant Private Healthcare GP VI, LLC, its General Partner By: /s/ Bihua Chen, Managing Member08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR